Health
globalreutersSeptember 27, 20241 Mins read
FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in Decades
globalreutersSeptember 27, 20241 Mins read 
Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety. The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics.
The post FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in Decades appeared first on MedCity News.
Related Articles
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
Kura Oncology already had a broad development plan for ziftomenib in leukemias,...
How Much More Would People Pay in Premiums if the ACA’s Enhanced Subsidies Expired?
Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace...
Everything You Need to Know About Hip Replacement Surgery in India
Hip replacement surgery is one of the most common and successful medical...
Speculation on RFK Jr. as HHS Secretary
From Tyler Cowen at Marginal Revolution: One of the problems with an...
Leave a comment